Fünf Chemotherapeutika in tierexperimentellen Untersuchungen zur Prävention und Therapie der Peritonealkarzinose

Zusammenfassung

Nach chirurgischer Resektion von soliden gastrointestinalen Tumoren (Magen-, Pankreas-, kolorektales Karzinom) stellen hohe lokale Rezidivraten im ehemaligen Tumorbett oder am Peritoneum ein noch immer ungelöstes Problem dar. So existieren zurzeit keine standardisierten Therapieprotokolle zur Prophylaxe oder Behandlung der Peritonealkarzinose.
In einem tierexperimentellen Modell an der Ratte wurden die fünf Chemotherapeutika Mitomycin, Cisplatin, 5-FU, Oxaliplatin und CPT-11 (je Chemotherapeutikum n = 24) hinsichtlich eines möglichen präventiven oder therapeutischen Potenzials bei Peritonealkarzinose nach intraperitonealer (i. p.) Applikation untersucht. Die Untersuchungen wurden in drei Gruppen (je Gruppe n = 8) mit zwei zusätzlichen Kontrollgruppen vorgenommen. In der ersten Gruppe wurden die Zytostatika direkt nach Tumorzellimplantation in die Peritonealhöhle appliziert. Eine frühe postoperative i. p. Chemotherapie (d 5, 15, 20) wurde in der zweiten Gruppe verabreicht. In der dritten Gruppe wurde ein späte i. p. Chemotherapie (d 15, 20, 25) über ein implantiertes Portsystem unter der Intention gegeben, eine bereits bestehende Peritonealkarzinose zu beeinflussen.
Die Ergebnisse zeigten, dass nach direkter intraoperativer i. p. Chemotherapie Mitomycin und Cisplatin hocheffektiv waren, ein i. p. Tumorwachstum zu vermeiden. Nach früher postoperativer, d. h. intermittierender i. p. Chemotherapie konnten die Zytostatika 5-FU und CPT-11 das i. p. Tumorwachstum am effektivsten reduzieren. Im Gegensatz dazu konnte keine der verwendeten Substanzen eine bereits manifestierte Peritonealkarzinose signifikant beeinflussen.
Die Daten sprechen dafür, dass neuere Substanzen hinsichtlich ihres Potenzials zur Beeinflussung des i. p. Tumorwachstums überprüft werden sollten. Dabei sollte ein Vergleich mit den etablierten Substanzen vorgenommen werden.

Abstract

High local recurrence rates within the previous tumor bed or at the peritoneum remain an unsolved problem after surgical resection of malignant gastrointestinal tumors such as gastric, colorectal or pancreatic carcinoma. Currently, there are no standardized treatment protocols available for the prevention or treatment of peritoneal carcinomatosis. In a basic experimental trial, mitomycin, cisplatin, 5-FU, oxaliplatin and CPT-11 were used to prevent or treat peritoneal carcinomatosis induced in rats.
Experiments were performed in three groups (n = 8 each) of animals plus two control groups. In the first group, Mitomycin, Cisplatin, 5-FU, Oxaliplatin and CPT-11 (n = 24 each) were applied directly following tumor cell implantation into the peritoneal cavity. In the second group, early postoperative intraperitoneal (i. p.) chemotherapy (day [d] 5, 10, 15 following surgical intervention for tumor cell transfer) was administered, whereas in the third group, late i. p. chemotherapy (d 15, 20, 25 following surgery) was given via a port-a-cath aiming for significant reduction of a visible, already established peritoneal carcinomatosis. Mitomycin and cisplatin were highly effective to prevent peritoneal carcinomatosis (direct application immediately after tumor cell transfer - 1^st treatment group). Using early postoperative i. p. chemotherapy (2^nd group), 5-FU and CPT-11 were shown to be significantly effective to reduce the intraperitoneal tumor spread. None of the cytostatic agents was able to decrease significantly an already generated peritoneal carcinomatosis (3^rd treatment group).
The results suggest that novel chemotherapeutic drugs should be proven for their potential to alter peritoneal metastases of GI tumors i) in comparison with established drugs and ii) depending on the application time and mode.

Peritonealkarzinose - lokale Chemotherapie - Mitomycin - Cisplatin - 5-FU - Oxaliplatin - CPT-11

Peritoneal carcinomatosis - local chemotherapy - Mitomycin - Cisplatin - 5-FU - Oxaliplatin - CPT-11

Literatur

• 1 Aparicio T, Kermorgant S, Dessirier V, Lewin M J, Lehy T. Matrix metalloproteinase inhibition prevents colon cancer peritoneal carcinomatosis development and prolongs survival in rats.  Carcinogenesis. 1999;  20 1445-1451
• 2 Benoit L, Duvillard C, Beltramo J L, Brunet-Lecomte P, Chauffert B. Intraperitoneal cisplatin plus epinephrine and surgical debulking for the treatment of andvanced peritoneal carcinomatosis in the rat.  Gastroenterol Clin Biol. 2000;  24 26-30
• 3 Cass A W, Million R R, Pfaff W W. Patterns of recurrence following surgery alone for adenocarcinoma of the colon and rectum.  Cancer. 1976;  37 2861-2865
• 4 Fass J, Jansen M, Zengel K, Reinecke T, Asshoff G, Schumpelick V. Results of intraperitoneal active charcoal-mitomycin C therapy of stomach carcinoma with serosa invasion.  Langenbecks Arch Chir. 1998;  115 (Suppl) 1363-1366
• 5 Guichard S, Chatelut E, Lochon I, Bugat R, Mahjoubi M, Canal P. Comparison of the pharmacocinetics and efficacy of Irinotecan after administration by the intravenous versus intraperitoneal route in mice.  Cancer Chemother Pharmacol. 1998;  42 165-170
• 6 Hagiwara A, Takahashi T, Kojima O, Sawai K, Yamaguchi T, Yamane T, Taniguchi H, Kitamura K, Noguchi A, Seiki K. et al . Prophylaxis with carbon-absorbed mitomycin against peritoneal recurrence of gastric cancer.  Lancet. 1992;  339 629-631
• 7 Horsell K W, Merten S, Clingan P, King D W, Morris D L. Peritonectomy and intraperitoneal chemotherapy in appendical and colorectal cancer.  Aust N Z J Surg. 1999;  69 729-732
• 8 Los G, Mutsaers P H, Ruevekamp M, McVie J G. The use of oxaliplatin versus cisplatin in intraperitoneal chemotherapy in cancers restricted to the peritoneal cavity in the rat.  Cancer Lett. 1990;  51 109-117
• 9 Malcolm A W, Perencevich N P, Olson R M, Hanley J A, Chaffey J T, Wilson R E. Analysis of recurrence patterns following curative resection for carcinoma of the colon and rectum.  Surg Gynecol Obstet. 1981;  152 131-136
• 10 Maruyama M, Takamatsu S, Sugano N, Ebuchi M, Endo M, Yuasa Y. Experimental Study on intraperitoneal sequential MTX/5-FU therapy for peritoneal seeding in comparison with intravenous administration.  Gan To Kagaku Yoho. 1997;  24 2131-2136
• 11 Michelassi F, Vannucci L, Ayala J J, Chappel R, Goldberg R. Local recurrence after curative resection of colorectal cancer.  Surgery. 1990;  108 787-793
• 12 Pescatori M, Mattana C, Maria G, Ferrara A, Lucibello L. Outcome of colorectal cancer.  Br J Surg. 1987;  74 370-372
• 13 Phillips R K, Hittinger R, Blesovsky L, Fry J S, Fielding L P. Local recurrence following 'curative' surgery for large bowel cancer: I. The overall picture.  Br J Surg. 1984;  71 12-16
• 14 Pross M, Lippert H, Mantke R, Kruger S, Gunther T, Marusch F, Halangk W, Schulz H U. A proteinase inhibitor decreases tumor growth in a laparoscopic rat model.  Surg Endosc. 2001;  15 882-885
• 15 Rosen H R, Jatzko G, Repse S, Potrc S, Neudorfer H, Sandbichler P, Zacherl J, Rabl H, Holzberger P, Lisborg P, Czeijka M. Adjuvant intraperitoneal chemotherapy with carbon-absorbed mitomycin in patients with gastic cancer: results of a randomized multicenter trial of the Austrian working group for surgical oncology.  J Clin Oncol. 1998;  16 2733-2738
• 16 Russell A H, Tong D, Dawson, Wisbeck W. Adenocarcinoma of the proximal colon. Sites of initial dissemination and patterns of recurrence following surgery alone.  Cancer. 1984;  200 85-90
• 17 Samel S, Singal A, Becker H, Post S. Problems with intraperitoneal chemotherapy for advanced gastric cancer.  Eur J Surg Oncol. 2000;  26 222-226
• 18 Sautner T, Hofbauer F, Depisch D, Schiessel R, Jakesz R. Adjuvant intraperitoneal cisplatin chemotherapy does not improve long-term survival after surgery for advanced gastric cancer.  J Clin Oncol. 1994;  12 970-974
• 19 Scheithauer W, Kornek G V, Marczell A, Karner J. Combined intravenous and intraperitoneal chemotherapy with 5-FU + Leucovorin vs 5-FU + levamisole for adjuvant therapy of resected colon carcinoma.  Br J Cancer. 1998;  77 1349-1354
• 20 Shiu M, Fortner J. Intraperitoneal hyperthermic treatment of implantated peritoneal cancer in rats.  Cancer Res. 1980;  40 4081-4048
• 21 Stein H J, Kraemer S JM, Feussner H, Siewert J R. Clinical value of diagnostic laparoscopy with laparoscopic ultrasound in patients with cancer of the esophagus or cardia.  J Gastrointest Surg. 1997;  1 167-173
• 22 Stipa S, Nicolanti V, Botti C. Local recurrence after curative resection of colorectal cancer: frequency, risk factors and treatment.  J Surg Oncol. 1991;  2 (Suppl) 155-160
• 23 Sugarbaker P H. Treatment of peritoneal carcinomatosis from colon or appendical cancer with induction intraperitoneal chemotherapy.  Cancer Treat Res. 1996;  82 317-325
• 24 Sugarbaker P H, Yonemura Y. Palliation with a glimmer of hope: management of resectable gastric cancer with peritoneal carcinomatosis.  Hepatogastroenterology. 2001;  48 1238-1247
• 25 Watson S A, Morris T M, Parsons S L, Steele R J, Brown P D. Therapeutic effect of the matrix metalloproteinase inhibitor, batimastat, in a human colorectal cancer ascites model.  Brit J Cancer. 1996;  74 1354-1358
• 26 Willet C G, Tepper J E, Cohen A M, Orlow E, Welch C E. Failure patterns following curative resection of colonic carcinoma.  Ann Surg. 1984;  200 685-690
• 27 Yonemura Y, Sawa T, Kinoshita K. Neoadjuvant chemotherapy for high grade advanced gastric cancer.  World J Surg. 1993;  17 256-261
• 28 Yoshikawa T, Yanoma S, Tsuburaya A, Kobayashi O, Sairenji M, Motohashi H, Noguchi Y. Angiogenesis inhibitor, TNP-470, suppresses growth of peritoneal disseminating foci.  Hepatogastroenterology. 2000;  47 298-302
• 29 Yu W, Whang I, Suh I, Averbach A, Chang D, Sugarbaker P H. Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer.  Ann Surg. 1998;  228 347-354